O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
+6.32%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$9.11B
AUM Growth
+$9.11B
(+10%)
Cap. Flow
+$635M
Cap. Flow
% of AUM
6.97%
Top 10 Holdings %
Top 10 Hldgs %
38.17%
Holding
140
New
19
Increased
34
Reduced
21
Closed
18
Top Buys
| 1 |
AGN
Allergan plc
AGN
|
$218M |
| 2 |
Cooper Companies
COO
|
$178M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
$92.3M |
| 4 |
SHPG
Shire pic
SHPG
|
$81.3M |
| 5 |
WMGI
Wright Medical Group Inc
WMGI
|
$74.1M |
Top Sells
| 1 |
ITMN
INTERMUNE INC
ITMN
|
$240M |
| 2 |
Viatris
VTRS
|
$172M |
| 3 |
AGN
ALLERGAN INC
AGN
|
$115M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
$89.3M |
| 5 |
Pfizer
PFE
|
$41.8M |
Sector Composition
| 1 | Healthcare | 88.25% |
| 2 | Financials | 0.07% |
| 3 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Gilead Sciences
GILD
$140B
| $400M | 4.18% | 3,762,200 +327,400 | +10% | +$34.9M |
|
2
Biogen
BIIB
$19.4B
| $394M | 4.11% | 1,190,100 +105,900 | +10% | +$35M |
|
3
Bristol-Myers Squibb
BMY
$96B
| $373M | 3.9% | 7,292,000 +103,000 | +1% | +$5.27M |
|
4
Amgen
AMGN
$155B
| $366M | 3.82% | 2,603,000 +358,000 | +16% | +$50.3M |
|
|
ICPT
5
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $351M | 3.67% | 1,485,000 -171,258 | -10% | -$40.5M |
|
|
AGN
6
DELISTED
Allergan plc
AGN
| $347M | 3.62% | 1,436,200 +904,200 | +170% | +$218M |
|
7
AbbVie
ABBV
$372B
| $316M | 3.3% | 5,478,000 +273,800 | +5% | +$15.8M |
|
|
SHPG
8
DELISTED
Shire pic
SHPG
| $316M | 3.3% | 1,219,000 +313,800 | +35% | +$81.3M |
|
|
CELG
9
DELISTED
Celgene Corp
CELG
| $315M | 3.29% | 3,328,000 +673,000 | +25% | +$63.8M |
|
10
HCA Healthcare
HCA
$94.5B
| $297M | 3.1% | 4,213,000 -300,000 | -7% | -$21.2M |
|
|
MDVN
11
DELISTED
MEDIVATION, INC.
MDVN
| $225M | 2.35% | 2,273,000 -173,600 | -7% | -$17.2M |
|
12
Illumina
ILMN
$15.8B
| $220M | 2.3% | 1,343,000 -43,000 | -3% | -$7.05M |
|
|
CFN
13
DELISTED
CAREFUSION CORPORATION
CFN
| $215M | 2.25% | 4,756,000 +1,085,000 | +30% | +$49.1M |
|
14
Thermo Fisher Scientific
TMO
$186B
| $206M | 2.15% | 1,691,400 +155,700 | +10% | +$18.9M |
|
|
RLYP
15
DELISTED
RELYPSA INC COM
RLYP
| $187M | 1.95% | 8,857,551 -1,084,000 | -11% | -$22.9M |
|
16
Intuitive Surgical
ISRG
$170B
| $178M | 1.86% | 386,400 -4,700 | -1% | -$2.17M |
|
|
17
Cooper Companies
COO
$13.4B
| $178M | 1.86% | +1,142,700 | New | +$178M |
|
18
Agilent Technologies
A
$35.7B
| $175M | 1.83% | 4,299,000 +1,168,700 | +37% | +$47.6M |
|
19
Perrigo
PRGO
$3.27B
| $172M | 1.8% | 1,144,700 -37,000 | -3% | -$5.56M |
|
|
AGN
20
DELISTED
ALLERGAN INC
AGN
| $160M | 1.67% | 897,700 -646,000 | -42% | -$115M |
|
21
Incyte
INCY
$16.5B
| $160M | 1.67% | 3,254,900 -245,500 | -7% | -$12M |
|
22
Merck
MRK
$210B
| $158M | 1.65% | 2,662,000 +124,000 | +5% | +$7.35M |
|
23
Ironwood Pharmaceuticals
IRWD
$214M
| $156M | 1.63% | 12,012,100 +3,076,200 | +34% | +$39.9M |
|
|
IPXL
24
DELISTED
Impax Laboratories, Inc.
IPXL
| $152M | 1.59% | 6,405,200 +989,600 | +18% | +$23.5M |
|
|
25
Vertex Pharmaceuticals
VRTX
$100B
| $152M | 1.58% | 1,350,000 +822,000 | +156% | +$92.3M |
|